Table 1.
Baseline Characteristics of People in This Study.
| Parameter | Personal CGM | No CGM | P value |
|---|---|---|---|
| N | 117 | 355 | |
| Age, mean (SD) | 49 (13) | 42 (15) | <.0001 |
| Sex (%) | |||
| Female | 53 | 58 | .3136 |
| Male | 47 | 42 | |
| Region (%) | |||
| Europe | 44 | 61 | .0016 |
| North America | 56 | 39 | |
| Smoking status (%) | |||
| Current | 4 | 12 | .0342 |
| Previous | 26 | 21 | |
| Never | 70 | 67 | |
| Body mass index (kg/m2), mean (SD) | 27.2 (4.1) | 26.0 (3.9) | .0070 |
| Duration of diabetes (yr), mean (SD) | 28 (12) | 23 (12) | .0004 |
| Total daily insulin dose (U/kg), mean (SD) | 0.60 (0.23) | 0.63 (0.24) | .2221 |
| HbA1c at baseline, mean (SD) | |||
| mmol/mol | 58.2 (5.7) | 58.4 (5.9) | .7174 |
| % | 7.48 (0.52) | 7.50 (0.54) | |
| Hypoglycemia unawareness a , n (%) | 20 (17) | 34 (10) | .0267 |
| Number of days CGM b worn (days), mean (SD) | 42 (7) | 41 (8) | .8173 |
| Percentage of time CGM b is active (%), mean (SD) | 95 (6) | 94 (6) | .3270 |
CGM, continuous glucose monitoring; HbA1c, glycated hemoglobin A1c.
a
According to the Clarke questionnaire, question 8. 14
b
Use of blinded CGM during 3 × 2 weeks.